ES3015371T3 - Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof - Google Patents
Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof Download PDFInfo
- Publication number
- ES3015371T3 ES3015371T3 ES18763383T ES18763383T ES3015371T3 ES 3015371 T3 ES3015371 T3 ES 3015371T3 ES 18763383 T ES18763383 T ES 18763383T ES 18763383 T ES18763383 T ES 18763383T ES 3015371 T3 ES3015371 T3 ES 3015371T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- compound
- hours
- days
- cefepime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762467752P | 2017-03-06 | 2017-03-06 | |
| US201762467750P | 2017-03-06 | 2017-03-06 | |
| US201762564990P | 2017-09-28 | 2017-09-28 | |
| US201762564989P | 2017-09-28 | 2017-09-28 | |
| PCT/US2018/020968 WO2018165048A1 (en) | 2017-03-06 | 2018-03-05 | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3015371T3 true ES3015371T3 (en) | 2025-05-05 |
Family
ID=63448038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18763383T Active ES3015371T3 (en) | 2017-03-06 | 2018-03-05 | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US11091505B2 (https=) |
| EP (1) | EP3592362B1 (https=) |
| JP (2) | JP7634934B2 (https=) |
| KR (1) | KR102603489B1 (https=) |
| CN (2) | CN110678186A (https=) |
| AU (1) | AU2018230991B2 (https=) |
| CA (1) | CA3055253A1 (https=) |
| ES (1) | ES3015371T3 (https=) |
| HR (1) | HRP20250459T1 (https=) |
| IL (2) | IL268981B2 (https=) |
| MA (1) | MA47743A (https=) |
| MY (1) | MY196966A (https=) |
| PH (1) | PH12019502037B1 (https=) |
| PL (1) | PL3592362T3 (https=) |
| SG (1) | SG11201908181XA (https=) |
| WO (1) | WO2018165048A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013355110B2 (en) | 2012-12-07 | 2017-11-09 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| EP2943204B1 (en) | 2013-01-10 | 2019-03-13 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
| EP2970340B1 (en) | 2013-03-14 | 2020-02-12 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2015191907A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2017044828A1 (en) | 2015-09-11 | 2017-03-16 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2018027062A1 (en) | 2016-08-04 | 2018-02-08 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| KR102603489B1 (ko) | 2017-03-06 | 2023-11-16 | 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 | 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도 |
| US11332485B2 (en) | 2017-05-26 | 2022-05-17 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2019226931A1 (en) | 2018-05-25 | 2019-11-28 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| EP3849562B1 (en) * | 2018-09-12 | 2024-06-26 | Venatorx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor |
| BR112021010095A2 (pt) | 2018-11-29 | 2021-09-28 | VenatoRx Pharmaceuticals, Inc. | Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1021454A (en) | 1911-01-23 | 1912-03-26 | Thomas Ernest Davis | Serving-table. |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| US7875642B2 (en) | 2004-01-26 | 2011-01-25 | Merck Sharp & Dohme Corp. | Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1 |
| HRP20212002T1 (hr) | 2004-03-30 | 2022-04-01 | Millennium Pharmaceuticals, Inc. | Sinteza estera i spojeva borove kiseline |
| CN1965838A (zh) * | 2005-11-17 | 2007-05-23 | 李海超 | 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物 |
| CN101129382B (zh) | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| CA2705393A1 (en) | 2007-11-13 | 2009-05-22 | Protez Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2009091856A2 (en) | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
| US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
| CA2807546C (en) | 2010-08-10 | 2022-08-23 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2013014497A1 (en) | 2011-07-26 | 2013-01-31 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
| KR101288157B1 (ko) | 2011-12-07 | 2013-07-19 | 백병하 | 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제 |
| JP5798495B2 (ja) | 2012-01-13 | 2015-10-21 | 住友理工株式会社 | 配線体接続構造体 |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| AU2013355110B2 (en) * | 2012-12-07 | 2017-11-09 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| KR20150103269A (ko) | 2013-01-04 | 2015-09-09 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| MX2015008627A (es) | 2013-01-04 | 2015-09-23 | Rempex Pharmaceuticals Inc | Derivados de acido boronico y usos terapeuticos de los mismos. |
| EP2943204B1 (en) | 2013-01-10 | 2019-03-13 | Venatorx Pharmaceuticals Inc | Beta-lactamase inhibitors |
| EP2970340B1 (en) | 2013-03-14 | 2020-02-12 | Venatorx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9120796B2 (en) * | 2013-10-02 | 2015-09-01 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| WO2015157618A1 (en) | 2014-04-11 | 2015-10-15 | The Texas A&M University System | Novel inhibitors of the new delhi metallo beta lactamase (ndm-1) |
| US20150361107A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Orally bioavailable beta-lactamase inhibitors |
| WO2015191907A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| JP6218204B2 (ja) | 2014-09-04 | 2017-10-25 | 塩野義製薬株式会社 | カテコール基を有するセファロスポリン類を含有する製剤 |
| EP3233869B1 (en) | 2014-12-19 | 2019-09-25 | Rempex Pharmaceuticals, Inc. | Apparatus and continuous flow process for production of boronic acid derivatives |
| WO2017044828A1 (en) | 2015-09-11 | 2017-03-16 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN105801610B (zh) | 2016-04-19 | 2018-05-18 | 武汉维舜医药科技有限公司 | 新型广谱β-内酰胺酶抑制剂 |
| MX389349B (es) | 2016-06-30 | 2025-03-20 | Qpex Biopharma Inc | Derivados de ácido borónico y usos terapéuticos de los mismos. |
| WO2018027062A1 (en) | 2016-08-04 | 2018-02-08 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| KR102603489B1 (ko) | 2017-03-06 | 2023-11-16 | 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 | 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도 |
| WO2019226931A1 (en) | 2018-05-25 | 2019-11-28 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| EP3849562B1 (en) | 2018-09-12 | 2024-06-26 | Venatorx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor |
| BR112021010095A2 (pt) | 2018-11-29 | 2021-09-28 | VenatoRx Pharmaceuticals, Inc. | Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas |
-
2018
- 2018-03-05 KR KR1020197029086A patent/KR102603489B1/ko active Active
- 2018-03-05 MY MYPI2019005139A patent/MY196966A/en unknown
- 2018-03-05 HR HRP20250459TT patent/HRP20250459T1/hr unknown
- 2018-03-05 PH PH1/2019/502037A patent/PH12019502037B1/en unknown
- 2018-03-05 CN CN201880030083.5A patent/CN110678186A/zh active Pending
- 2018-03-05 US US16/491,116 patent/US11091505B2/en active Active
- 2018-03-05 AU AU2018230991A patent/AU2018230991B2/en active Active
- 2018-03-05 IL IL268981A patent/IL268981B2/en unknown
- 2018-03-05 CN CN202311312855.3A patent/CN117398398A/zh active Pending
- 2018-03-05 PL PL18763383.9T patent/PL3592362T3/pl unknown
- 2018-03-05 IL IL301591A patent/IL301591B2/en unknown
- 2018-03-05 ES ES18763383T patent/ES3015371T3/es active Active
- 2018-03-05 SG SG11201908181X patent/SG11201908181XA/en unknown
- 2018-03-05 WO PCT/US2018/020968 patent/WO2018165048A1/en not_active Ceased
- 2018-03-05 EP EP18763383.9A patent/EP3592362B1/en active Active
- 2018-03-05 MA MA047743A patent/MA47743A/fr unknown
- 2018-03-05 JP JP2019547093A patent/JP7634934B2/ja active Active
- 2018-03-05 CA CA3055253A patent/CA3055253A1/en active Pending
-
2021
- 2021-06-21 US US17/353,377 patent/US11820784B2/en active Active
-
2023
- 2023-01-20 JP JP2023007546A patent/JP2023061946A/ja active Pending
- 2023-09-27 US US18/476,050 patent/US12187752B2/en active Active
-
2024
- 2024-11-25 US US18/959,220 patent/US20250320235A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3015371T3 (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| ES2820827T3 (es) | Formas sólidas de un compuesto modulador de quinasas | |
| AU2019202144A1 (en) | Solid forms of {(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino}acetic acid, compositions, and uses thereof | |
| CN102933205B (zh) | 西洛他唑共晶和组合物 | |
| EA021989B1 (ru) | Замещенные индолы, противовирусный активный компонент, способ получения и применения | |
| HK40097446A (zh) | 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 | |
| EA048377B1 (ru) | Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения | |
| EA042812B1 (ru) | Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения | |
| BR112019018447B1 (pt) | Forma cristalina anidra, mono-hidratada, composições farmacêuticas e usos das mesmas | |
| HK40020554A (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| HK40020554B (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| CN102770416B (zh) | 美他沙酮共晶体 | |
| HK40013654A (en) | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof | |
| CN107586293A (zh) | 含硫二苯并噻嗪生物碱类化合物及其用途 | |
| HK40100619A (zh) | 一种p2x3抑制剂化合物及其盐、多晶型和用途 | |
| CN106749481A (zh) | 甘草次酸类新化合物实体及其用途 | |
| HK1248223B (en) | Solid forms of a compound modulating kinases | |
| HK1248223A1 (en) | Solid forms of a compound modulating kinases | |
| NZ759132B2 (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |